-
3SBio Inc. Secures Licensing Deal with Sunshine Lake Pharma for Clifutinib Commercialization
•
China-based 3SBio Inc. (HKG: 1530) has announced a licensing deal with fellow Chinese firm Sunshine Lake Pharma Co., Ltd., a member of HEC Group (SHA: 600673), concerning the commercialization of clifutinib in mainland China. Under the terms of the agreement, 3SBio will handle the commercialization efforts for the drug, paying…
-
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
•
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round of the national volume-based procurement (VBP) program. Hospitals are required to begin providing details of the volumes required for a list of 41 drugs across 181 specifications starting from January 13. This round focuses entirely…
